| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/29/2008 | WO2008062905A2 Heteromonocyclic compound and use thereof |
| 05/29/2008 | WO2008062861A1 Extract powder of indigo-containing plant, method for production thereof, and use thereof |
| 05/29/2008 | WO2008062830A1 Spiroquinone compound and pharmaceutical composition |
| 05/29/2008 | WO2008062814A1 Hydrogen-dissolved aqueous solution and method for prolonging the life duration of hydrogen dissolved in the aqueous solution |
| 05/29/2008 | WO2008062740A1 Nitrogenated fused ring compound and use thereof |
| 05/29/2008 | WO2008062739A1 Pyrazoles and use thereof as drugs |
| 05/29/2008 | WO2008062559A1 Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic |
| 05/29/2008 | WO2008061671A2 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels |
| 05/29/2008 | WO2008061480A1 Novel mangiferin calcium salts, the method for its preparation and its use |
| 05/29/2008 | WO2008061456A1 The folacin-metformin compound and its manufacture |
| 05/29/2008 | WO2008061428A1 The pharmaceutical formulations, use and preparation of triacontanol |
| 05/29/2008 | WO2008061355A1 Glp-1 depot systems, and methods of manufacture and uses thereof |
| 05/29/2008 | WO2008061308A1 Protein tyrosine phosphatase modulators |
| 05/29/2008 | WO2008061299A1 Method of treating diabetes |
| 05/29/2008 | WO2008045564A3 Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
| 05/29/2008 | WO2008041003A3 Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorers asociated therewith |
| 05/29/2008 | WO2008038302A3 Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. |
| 05/29/2008 | WO2008020709A9 Composition and functional food for prevention and treatment of diabetic complications |
| 05/29/2008 | WO2008016123A1 GSK-3β INHIBITOR |
| 05/29/2008 | WO2008011562A3 Composition having effect of treating, preventing, or improving diabetes or diabetic complication and drink comprising the same |
| 05/29/2008 | WO2006137597A9 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
| 05/29/2008 | US20080125477 7-(acryloyl) indole compositions and methods of making and using same |
| 05/29/2008 | US20080125472 Use of an inhibitor of the renin-angiotensin system; candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan, and eprosartan |
| 05/29/2008 | US20080125468 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses |
| 05/29/2008 | US20080125466 Useful in the treatment of conditions associated with pathological receptor activation; inhibiting binding of vanilloid ligand to a capsaicin receptor; (4-tert-Butyl-phenyl)-[1,1-dioxo-6-(3-trifluoromethyl-pyridin-2-yl)-1H-1?6-benzo[d]isothiazol-3-yl]-amine |
| 05/29/2008 | US20080125455 disorders of the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus; sleep apnea; (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine and (S)-1-[1-(1,2,3,6,7,8-hexahydrocyclopent[g]indolyl)]-2-propylamine |
| 05/29/2008 | US20080125434 E. g., 6-(4-benzooxazol-2-yl-piperazin-1-yl)pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide; diseases such as related to dyslipidemia and metabolism disorders of lipid; especially diseases related to elevated lipid levels, cardiovascular disease, antidiabetic agents; obesity; anticholesterol agent |
| 05/29/2008 | US20080125429 1-{[5-[4-(Methylsulfonyl)phenoxy]-2-(2-pyridinyl)-1H-benzimidazol-6-yl]methyl}-5-thioxo-2-pyrrolidinone;glucokinase activator; antidiabetic agents; obesity; prevention of retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis; antiischemic agents; cardiotonic agents |
| 05/29/2008 | US20080125425 Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors |
| 05/29/2008 | US20080125418 Benzimidazole derivatives and their use as kdr kinase protein inhibitors |
| 05/29/2008 | US20080125412 Containing a diazacycloalkane ring, especially a 1,4-diazepane ring, e.g., N-p-((4-(alpha-phenylmethoxycarbonylmethyl)-1,4-diazepan-1-yl)phenyl)-o-biphenylcarboxamide, for the treatment of hyperlipidemia, obesity and type II diabetes. |
| 05/29/2008 | US20080125403 Method of Treating Men with Metabolic and Anthropometric Disorders |
| 05/29/2008 | US20080125387 Administering vector system that directs regulated erythropoietin (Epo) gene therapy in a manner that physiologically corrects the hematocrit levels in a patient in need of anemia treatment |
| 05/29/2008 | US20080125371 Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) |
| 05/29/2008 | US20080125369 Soluble t cell receptors |
| 05/29/2008 | US20080125361 Stable Formulations Of Peptides |
| 05/29/2008 | US20080125353 Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus |
| 05/29/2008 | US20080124743 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (u1) |
| 05/29/2008 | US20080124416 Therapeutic composition from goji (lycium barbarum l.), methods of making and using |
| 05/29/2008 | US20080124415 comprises proanthocyanidin; drink or food for fat combustion acceleration, body fat reduction or adiposity prevention |
| 05/29/2008 | US20080124347 Insulinotropic peptide conjugate using carrier substance |
| 05/29/2008 | US20080124346 Chimeric metal binding protein for use in prevention and treatment of cancer, diabetes, cardiovascular disease, obesity, metabolic disease, neurodegenerative disease, gastrointestinal disease, autoimmune disease, rheumatological disease and infectious disease. |
| 05/29/2008 | DE10113974B4 Verwendung von racemischer und enantiomerenreiner Dihydroliponsäure oder deren Derivate zur Körpergewichtsreduzierung und/oder zur Verringerung des Appetits The use of racemic and enantiomerically pure dihydrolipoic acid or their derivatives for body weight reduction and / or for the reduction of appetite |
| 05/29/2008 | CA2670404A1 Heteromonocyclic compound and use thereof |
| 05/29/2008 | CA2669347A1 Methods for treating pompe disease |
| 05/29/2008 | CA2669124A1 Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| 05/29/2008 | CA2666371A1 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition |
| 05/29/2008 | CA2650227A1 Substituted pyrazolopyrimidines |
| 05/28/2008 | EP1925667A1 Specific protein of the pancreatic beta cells of the Langerhans' islands and its applications |
| 05/28/2008 | EP1925617A1 Heterocyclic compound, and production process and use thereof |
| 05/28/2008 | EP1925333A1 Intradermal delivery of substances |
| 05/28/2008 | EP1925312A1 Drug for treatment of complications of diabetes mellitus |
| 05/28/2008 | EP1925311A1 Use of a plant extract or plant juice |
| 05/28/2008 | EP1925308A1 Low hygroscopic aripiprazole (crystal G) drug substance and processes for the preparation thereof |
| 05/28/2008 | EP1925303A2 Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure |
| 05/28/2008 | EP1924579A2 Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives |
| 05/28/2008 | EP1924563A1 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 |
| 05/28/2008 | EP1924561A2 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| 05/28/2008 | EP1924560A1 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| 05/28/2008 | EP1924556A2 Crystalline forms of atorvastatin |
| 05/28/2008 | EP1924294A2 Compositions and their uses directed to ptpru |
| 05/28/2008 | EP1924293A1 Composition and method for prevention and treatment of type i diabetes |
| 05/28/2008 | EP1924286A1 Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
| 05/28/2008 | EP1924274A1 Modulation of cell fates and activities by phthalazinediones |
| 05/28/2008 | EP1924262A2 Methods and formulations for modulating lyn kinase activity and treating related disorders |
| 05/28/2008 | EP1924258A1 IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF |
| 05/28/2008 | EP1863817B1 Substituted, bicyclic 8-pyrrolidino-benzimidazoles, method for their production and their use as medicaments |
| 05/28/2008 | EP1546098B1 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 05/28/2008 | EP1496898B1 Tyrosine kinase inhibitors |
| 05/28/2008 | EP1494992B1 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 05/28/2008 | EP1473305B1 Novel glutamate receptor and utilization thereof |
| 05/28/2008 | EP1420020B1 4-oxoimidazolidine-2-spiropiperidine derivative |
| 05/28/2008 | EP1399155B1 Small molecules useful in the treatment of inflammatory disease |
| 05/28/2008 | EP1368063B1 Complex of modafinil and cyclodextrin |
| 05/28/2008 | EP1326630B1 Use of glp-2 peptides |
| 05/28/2008 | CN101189337A Ghrelin binding nucleic acids |
| 05/28/2008 | CN101189236A Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof |
| 05/28/2008 | CN101189231A Novel cyclic aminophenylalkanoic acid derivative |
| 05/28/2008 | CN101189226A Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists |
| 05/28/2008 | CN101189218A Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors |
| 05/28/2008 | CN101189211A Quinoline derivatives as NK3 anatgonists |
| 05/28/2008 | CN101189210A Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors |
| 05/28/2008 | CN101189019A Peptide having anti-anxiety effect and method for screening thereof |
| 05/28/2008 | CN101189007A Tetrahydrothiopyrano pyrazole cannabinoid modulators |
| 05/28/2008 | CN101189005A Combinations of a squalene synthase inhibitor and a HMG-CoA reductase inhibitor for treating hyperlipidemia |
| 05/28/2008 | CN101186596A Novel compound tatarine D and separating identification method thereof |
| 05/28/2008 | CN101185723A Traditional Chinese medicine preparation for treating diabetic retina affection |
| 05/28/2008 | CN101185701A Chemical medicine and natural medicine composition for treating diabetes chronic complication and preparation method thereof |
| 05/28/2008 | CN101185688A Application of seeds of Hovenia acerba extraction in medicine for resisting senility |
| 05/28/2008 | CN101185665A Method for preparing total flavone of bidens bipinnata |
| 05/28/2008 | CN101185662A Method and use for preparing novel medicine for treating diabetes prepared from tuber fern |
| 05/28/2008 | CN101185659A Intermediate compound of a traditional Chinese medicinal preparation and preparation method and application thereof |
| 05/28/2008 | CN101185658A Intermediate compound of a liquid state traditional Chinese medicinal preparation and preparation method and application thereof |
| 05/28/2008 | CN101185655A Medicinal composition for treating diabetes chronic complication and preparation method thereof |
| 05/28/2008 | CN101185646A Pharmaceutical compositions of amlodipine and atorvastatin |
| 05/28/2008 | CN101185642A Glucosamine lysine selenium salt and production process |
| 05/28/2008 | CN101185641A Atorvastatin calcium capsule and preparation method |
| 05/28/2008 | CN101185511A Method for making health care instant noodles food with enterogastric micro-ecological regulating action |
| 05/28/2008 | CN101185463A Fat-reducing health care breakfast milk |
| 05/28/2008 | CN100390286C Novel enzyme gene and its expression product |